Humber and North Yorkshire ICB have published details of the new primary care weight management pathway which is now available for referrals.
Eligibility criteria are set by NHS England and for the first cohort, the eligibility criteria are:
- A Body Mass Index (BMI) of ≥40 kg/m2 (reduce threshold by 2.5 kg/m2 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds)
and - at least 4 ‘qualifying’ comorbidities:
➢ Atherosclerotic cardiovascular disease (ASCVD)
➢ Hypertension
➢ Dyslipidaemia
➢ Obstructive Sleep Apnoea (OSA)
➢ Type 2 diabetes mellitus (T2D)
Tirzepatide should only be prescribed in line with the Humber and North Yorkshire Area Prescribing formulary status, i.e., tirzepatide (all strengths) pre-filled pen devices for subcutaneous injection for overweight and obesity is approved as ‘red-specialist use only’, as part of an ICB-approved commissioned service – the model described above is the current ICB-approved commissioned service.
Eligible patients can self-refer to the service using an online self-referral form – this is the preferred option. GP practices can also refer eligible patients via a referral form on GP computer systems via Ardens.
Full details can be found in the update announcement from HNY ICB.
09/10/2025
Comments are closed.